Jana Slavina Farmer (Partner-New York, NY) and Daniel Tranen (Partner-St. Louis, MO) collaborated on “The Shifting Landscape of Data Privacy Regulation in the Life Sciences Industry,” which was recently published in the Pharmaceutical Compliance Monitor, the only publication that spotlights regulatory and compliance news and developments for the pharmaceutical, biotechnology and medical device communities. The authors conclude: “While the costs of achieving compliance may be high, the risk of regulatory fines and litigation is not the only driver of compliance. Increasingly, businesses view the consumer trust that may be earned by building a mature privacy program as a competitive advantage, which, moreover, is increasingly taken into account in business valuations.”

Read the Article.